Sigma-Aldrich Corp

Sigma-Aldrich reports higher earnings

Sigma-Aldrich's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Sigma-Aldrich finished China distribution facility, products beginning to ship

Sigma-Aldrich reports 15% quarterly profit jump

Sigma-Aldrich (NASDAQ: SIAL) Reports Diluted EPS of $0.89, a 17% Increase, and 5% Sales Growth for Q4 2011. Full Year 2011 Diluted EPS Increased 14%. 2012 Diluted EPS Expected to Increase to $3.90 to $4.05

Sigma-aldrich Corp (SIAL) Tops Q4 EPS by 2c; Guide FY12 EPS

Sigma-Aldrich: Upside Potential Outweighs Downside Risk At The Current Price

Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences

Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences

TriLink Enters Into Distribution Agreement With Sigma-Aldrich

Rabbit Anti-Pan Cadherin Antibody from Sigma-Aldrich, used in Immunofluorescence

In Search Of Rising Dividends: Sigma Aldrich

Sigma to Acquire BioReliance - Analyst Blog

Sigma to Acquire BioReliance

Sigma-Aldrich Corporation Announces Q4 Conference Call

Sigma-Aldrich Corporation Announces Q4 Conference Call

Detour Your Way to the CEO Spot

Sigma-Aldrich acquires bio testing company

Sigma-Aldrich To Acquire BioReliance; Extending Its Reach Into Biopharmaceutical Testing And Services

Sigma-Aldrich Buys Pharmaceutical Testing and Services Company, BioReliance Holdings

Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation

Sigma-Aldrich (SIAL) to Acquire BioReliance Holdings in $350M Deal

In Brief This Week: Sigma-Aldrich; CLC Bio; Exiqon; Adaptive TCR; Evogene

Leerink Swann Downgrades Sigma-Aldrich (SIAL) to Market Perform; Europe A Sore Spot For 2012, SIAL Overexposed

Sigma-Aldrich downgraded to Market Perform from Outperform at Leerink

U.S. Jobs Outlook Improves Again: 10 Stocks That May Benefit

Leerink's life science tools and diagnostics analyst to hold a conference call

Sigma-Aldrich Corporation to Present at Upcoming Investor Conference

Sigma-Aldrich Corporation to Present at Upcoming Investor Conference

Sigma(R) Life Science Announces Gene Knockout Rat Models For Cardiovascular, Diabetes And Atherosclerosis Research

Sigma® Life Science Announces Gene Knockout Rat Models for Cardiovascular, Diabetes and Atherosclerosis Research

Sigma-Aldrich management to meet with Mizuho

CLSA Upgrades Sigma-Aldrich (SIAL) to Buy

Sigma-Aldrich upgraded to Buy from Outperform at CLSA

Will Qiagen's Restructuring Address The Real Problems? (QGEN, SIAL, VIVO, GPRO, LIFE, ABT, ILMN, BDX, TMO, CPHD)

Diffinity GenomicsT and Sigma-Aldrich® Sign Global Distribution Agreement for RapidTip®

Sigma® Life Science Launches The Most Comprehensive Antibody Array For Neurodegenerative Disorders And Neuronal Development

Cramer's 'Mad Money' Recap: Low-Risk Stocks That Reward (Final)

'Mad Money Lightning Round': Go With US Bancorp

Sigma-Aldrich initiated with an Overweight at JP Morgan